March 9, 2023 01:20 PM ESTUpdated 02:39 PM

Simultaneous advice from FDA and EMA? Very few companies go that route with new drugs, review finds

Zachary Brennan

Senior Editor

Officials from the US FDA and European Medicines Agency put together an overview of the simultaneous scientific reviews from both agencies over a five-year window …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Simultaneous advice from FDA and EMA? Very few companies go that route with new drugs, review finds

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Si­mul­ta­ne­ous ad­vice from FDA and EMA? Very few com­pa­nies go that route with new drugs, re­view finds

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Simultaneous advice from FDA and EMA? Very few companies go that route with new drugs, review finds

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data